This test competes with the Grail, which has been around for a couple of years. Here is the NYT’s take on both. They are calibrated to minimize the rate of false alarma, which means they miss more actual disease too. As the article says, they are not yet good enough to compete with invasive screening like colonoscopies.
I’d call these tests a diagnostic lottery ticket, similar to full body MRIs and CTs. You’re paying $700-$1000 for a tiny chance that the test will catch something. As the article says, the tests are best for firemen and other people who are high risk for specific diseases that these tests detect.